Literature DB >> 9435693

Cl- channels in basolateral renal medullary membranes. XII. Anti-rbClC-Ka antibody blocks MTAL Cl- channels.

C J Winters1, L Zimniak, W B Reeves, T E Andreoli.   

Abstract

Cl- channels in the medullary thick ascending limb (MTAL) studied by either patch-clamp technique or reconstitution into lipid bilayers are activated by increases in intracellular Cl- concentrations. rbClC-Ka, a ClC Cl- channel, may represent this channel. We therefore evaluated the role of rbClC-Ka in transcellular MTAL Cl- transport in two separate ways. First, an antibody was raised against a fusion protein containing a 153-amino acid fragment of rbClC-Ka. Immunostaining of rabbit kidney sections with the antibody was localized to basolateral regions of MTAL and cortical thick ascending limb (CTAL) segments and also to the cytoplasm of intercalated cells in the cortical collecting duct. Second, Cl- uptake and efflux were measured in suspensions of mouse MTAL segments. Cl- uptake was bumetanide sensitive and was stimulated by treatment with a combination of vasopressin + forskolin + dibutyryl adenosine 3',5-cyclic monophosphate (DBcAMP). Cl- efflux was also increased significantly by vasopressin + forskolin + DBcAMP from 114 +/- 20 to 196 +/- 36 nmol.mg protein-1.45 s-1 (P = 0.003). Cl- efflux was inhibited by the Cl- channel blocker diphenylamine-2-carboxylate (154 +/- 26 vs. 70 +/- 21 nmol.mg protein-1.45 s-1, P = 0.003). An anti-rbClC-Ka antibody, which inhibits the activity of MTAL Cl- channels in lipid bilayers, reduced Cl- efflux from intact MTAL segments (154 +/- 28 vs. 53 +/- 14 nmol.mg protein-1.45 s-1, P = 0.02). These results support the view that rbClC-Ka is the basolateral membrane Cl- channel that mediates vasopressin-stimulated net Cl- transport in the MTAL segment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9435693     DOI: 10.1152/ajprenal.1997.273.6.F1030

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  Cl- channels in basolateral TAL membranes. XIX. Cytosolic Cl- regulates mmCIC-Ka and mcCIC-Ka channels.

Authors:  C J Winters; M V Mikhailova; T E Andreoli
Journal:  J Membr Biol       Date:  2003-09-15       Impact factor: 1.843

2.  Stimulation of Ca2+-sensing receptor inhibits the basolateral 50-pS K channels in the thick ascending limb of rat kidney.

Authors:  Shumin Kong; Chengbiao Zhang; Wennan Li; Lijun Wang; Haiyan Luan; Wen-Hui Wang; Ruimin Gu
Journal:  Biochim Biophys Acta       Date:  2011-10-25

3.  Parallel down-regulation of chloride channel CLC-K1 and barttin mRNA in the thin ascending limb of the rat nephron by furosemide.

Authors:  Konrad Wolf; Martina Meier-Meitinger; Tobias Bergler; Hayo Castrop; Helga Vitzthum; Günter A J Riegger; Armin Kurtz; Bernhard K Krämer
Journal:  Pflugers Arch       Date:  2003-05-21       Impact factor: 3.657

4.  CYP-omega-hydroxylation-dependent metabolites of arachidonic acid inhibit the basolateral 10 pS chloride channel in the rat thick ascending limb.

Authors:  Rui-Min Gu; Lei Yang; Yunhong Zhang; Lijun Wang; Shumin Kong; Chengbiao Zhang; Yuanyuan Zhai; Mingxiao Wang; Peng Wu; Liping Liu; Feng Gu; Jiye Zhang; Wen-Hui Wang
Journal:  Kidney Int       Date:  2009-07-29       Impact factor: 10.612

5.  Angiotensin II stimulates basolateral 10-pS Cl channels in the thick ascending limb.

Authors:  Peng Wu; Mingxiao Wang; Haiyan Luan; Lili Li; Lijun Wang; Wen-Hui Wang; Ruimin Gu
Journal:  Hypertension       Date:  2013-04-08       Impact factor: 10.190

6.  Chloride channels in basolateral TAL membranes. XVIII. Phenylglyoxal induces functional mcCIC-Ka activity in basolateral MTAL membranes.

Authors:  C J Winters; T E Andreoli
Journal:  J Membr Biol       Date:  2003-09-15       Impact factor: 1.843

7.  Insulin-like growth factor-1 (IGF-1) inhibits the basolateral Cl channels in the thick ascending limb of the rat kidney.

Authors:  Lijun Wang; Wennan Li; Shumin Kong; Peng Wu; Chengbiao Zhang; Li Gu; Mingxiao Wang; WenHui Wang; Ruimin Gu
Journal:  Biochim Biophys Acta       Date:  2012-05-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.